Xtant Medical Hldgs Stock (AMEX:XTNT), Trade Ideas

Xtant Medical Hldgs

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Equities

News

Offerings

Markets

General

XTNT

Xtant Medical Holdings, Inc. (AMEX: XTNT) entered into a securities purchase agreement with accredited investors to sell shares of its common stock in a 

Xtant Medical Raises $15M Via Equity Offering

Penny Stocks

Health Care

Movers

SRGA

Medtech Firm Surgalign Holdings Inc (NASDAQ: SRGA) has entered into an asset purchase agreement to sell its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors&#39; hardware business outside of the U.S.

Surgalign Files For Bankruptcy, Agrees To Sell Global Hardware &amp; Biologics Business

Small Cap

Pre-Market Outlook

Trading Ideas

ACOR

AGFY

AKLI

AKUS

AUID

AVCT

AVEO

BOAS

COMS

COSM

DBGI

DBTX

DFLI

DLPN

DRUG

EQOS

ERNA

GSUN

HLBZ

HUDI

IMRA

INPX

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

KULR

LEGN

MYNA

NCLH

NMTR

NUWE

Nuveen California Dividend Advantage Municipal Fund 2

NXTP

OBLG

QBTS

QNRX

RIBT

RMED

SFBS

SLRX

SMTS

STAB

TENX

TRMR

VENA

VIGL

WALD

XAIR

ZFOX

Gainers


	COMSovereign Holding Corp. (NASDAQ: COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Monday.


Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Holdings Inc

Baird analyst Luke Junk maintains Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) with a Outperform and lowers the price target from $140 to $137.

Price Target

Analyst Ratings

Baird Maintains Outperform on Visteon, Lowers Price Target to $137

Wells Fargo analyst Steven Cahall maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Equal-Weight and lowers the price target from $47 to $43.

CMCSA

Wells Fargo Maintains Equal-Weight on Comcast, Lowers Price Target to $43

Baird analyst Richard Eastman maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Outperform and raises the price target from $110 to $120.

Baird Maintains Outperform on Teradyne, Raises Price Target to $120

Benchmark analyst Daniel Kurnos maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and lowers the price target from $115 to $105.

ROKU

Benchmark Maintains Buy on Roku, Lowers Price Target to $105

Baird analyst David Manthey maintains Stericycle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCL#NASDAQ">SRCL</a>) with a Neutral and lowers the price target from $62 to $55.

SRCL

Baird Maintains Neutral on Stericycle, Lowers Price Target to $55

WIIM

SAIA

Saia shares are trading lower lower after the company reported worse-than-expected Q1 financial results.

Charlie Munger, the venerable billionaire and right-hand man of Warren Buffett, was famous for his sharp wit as he was for his wealth. Over the years, Munger shared plenty of eyebrow-raising opinions on financial matters, sparking discussions and debates among investors and the public alike. Let's dive into some of his most controversial takes on money and investing.
Bitcoin is rat poison
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012404/image-218-1024x585.png" alt="" class="wp-image-309936" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012404/image-218-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012404/image-218-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012404/image-218-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012404/image-218-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012404/image-218.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Charlie Munger famously described Bitcoin as rat poison: Image Generated Via Dall-E</figcaption></figure>
See Also: <a href="https://www.benzinga.com/news/24/04/38392548/ups-earnings-show-the-weight-of-170-000-salaries-while-it-learns-to-navigate-shipping-slump?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">UPS Earnings Show The Weight Of $170,000 Compensation While It Learns To Navigate Shipping Slump (UPDATED</a>
Charlie Munger&#8217;s disdain for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is palpable and well-documented. He famously described the cryptocurrency as &#8220;rat poison squared,&#8221; expressing skepticism over its value and stability. Munger&#8217;s criticism stems from a belief that Bitcoin lacks the intrinsic attributes of a sound investment, viewing it instead as a speculative tool that attracts charlatans and speculators.
Opinion on Benjamin Graham
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012410/image-219-1024x585.png" alt="" class="wp-image-309937" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012410/image-219-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012410/image-219-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012410/image-219-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012410/image-219-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012410/image-219.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Munger and Buffett both diverged from Benjamin Graham despite being considered his disciples: Image Generated Via Dall-E</figcaption></figure>
Despite being a disciple of Benjamin Graham, the father of value investing, Munger has occasionally diverged from his teachings. Buffett and Munger diverged from his classic investing principles over time, leading Berkshire Hathaway to success. While Graham aimed to create a system accessible to all, Buffett and Munger embraced a strategy involving interaction with management, a departure from Graham&#8217;s preference. Graham&#8217;s era faced fewer regulations and more widespread fraud, fostering his skepticism toward management statements and his preference for bonds over stocks. Hence, Buffett and Munger&#8217;s reliance on character assessments and management dialogue contrasted Graham&#8217;s approach.
Limited opportunities in life for investing
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012425/image-220-1024x585.png" alt="" class="wp-image-309938" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012425/image-220-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012425/image-220-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012425/image-220-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012425/image-220-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012425/image-220.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Munger was a believer in snagging the opportunities offered by life, Image Generated Via Dall-E</figcaption></figure>
Munger believes that good investment opportunities are rare and that when they occur, one should invest heavily. His philosophy was that it was not a game with unlimited opportunities. He suggested that investors should be highly selective and act decisively when the right chance comes along. This viewpoint underscores the importance of patience and precision in building wealth.
Opinion on buying a fancy house
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012437/image-221-1024x585.png" alt="" class="wp-image-309939" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012437/image-221-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012437/image-221-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012437/image-221-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012437/image-221-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012437/image-221.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Charlie Munger was not a proponent of purchasing a fancy house. Image Generated Via Dall-E</figcaption></figure>
Munger, in his lifetime, deliberately embraced a modest lifestyle, eschewing opulent living despite his immense wealth and professional success. Over 70 years, he resided in the same unassuming home, diverging from the extravagant norms of affluence. Munger, echoing his colleague Warren Buffett&#8217;s sentiments, observed that grandeur often failed to enhance happiness, reinforcing his commitment to simplicity.
Views on the stock market&#8217;s future
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012452/image-222-1024x585.png" alt="" class="wp-image-309940" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012452/image-222-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012452/image-222-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012452/image-222-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012452/image-222-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26012452/image-222.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Munger was known for sometimes having a pessimistic outlook on the stock market&#8217;s future, Image Generated Via Dall-E</figcaption></figure>
Munger is known for his cautious, sometimes pessimistic outlook on the stock market's sustainability. During his later life, he highlighted the increasing complexity of investing. Munger noted that achieving perfection in investing is challenging due to market dynamics and competition. He observed a shift towards a more competitive landscape, with fewer opportunities to outperform market indices like the S&amp;P. Reflecting on past times, Munger recalled a simpler era where steady returns were more achievable, but he cautioned against expecting similar results in the future
Read Next: <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Q1 Earnings Highlights: EV Giant Misses Wall Street Estimates, Makes Cost Cuts, Invests In AI, Speeds Launch Of New Models</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Entertainment

Education

$BTC

Charlie Munger Was Known To Always Speak His Mind: These Were His 5 Most Controversial Takes On Money

Baird analyst Peter Arment maintains Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) with a Neutral and raises the price target from $475 to $505.

Baird Maintains Neutral on Northrop Grumman, Raises Price Target to $505

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and lowers the price target from $90 to $80.

FIVN

Rosenblatt Maintains Buy on Five9, Lowers Price Target to $80

BALL

Ball shares are trading higher after the company reported better-than-expected Q1 revenue results.

Baird analyst Michael Halloran maintains Graco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGG#NYSE">GGG</a>) with a Neutral and lowers the price target from $90 to $87.

Baird Maintains Neutral on Graco, Lowers Price Target to $87

RBC Capital analyst Mike Dahl maintains Whirlpool (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) with a Underperform and lowers the price target from $85 to $79.

RBC Capital Maintains Underperform on Whirlpool, Lowers Price Target to $79

Baird analyst Ben Kallo maintains California Water Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWT#NYSE">CWT</a>) with a Outperform and raises the price target from $52 to $55.

Baird Maintains Outperform on California Water Servs Gr, Raises Price Target to $55

Rosenblatt analyst Barton Crockett maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Neutral and maintains $45 price target.

Rosenblatt Maintains Neutral on Comcast, Maintains $45 Price Target

Guidance

TNET

TriNet Group Sees Q2 Adjusted Diluted EPS Of $1.00-$1.50 Vs. $1.57 Estimate; Lowers FY24 Adjusted Diluted EPS Outlook To $5.25-$6.80 From Prior View Of $5.80-$7.35 (Estimate: $6.65 )

As of April 26, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.  
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUSN#NASDAQ">FUSN</a>)</h3>
<ul>
<li>AstraZeneca, through a subsidiary, will acquire all of Fusion&#8217;s outstanding shares for a price of $21.00 per share in cash at closing plus a non-transferable CVR representing the contingent right to receive $3.00/share in cash payable upon the achievement of a specified regulatory milestone, pursuant and subject to the terms and conditions of a contingent value rights agreement. The company's stock gained around 408% over the past six months and has a <a href="https://www.benzinga.com/quote/FUSN">52-week high of $21.55</a>.</li>
<li>RSI Value: 78.74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>FUSN Price Action: Shares of Fusion Pharmaceuticals closed at $21.40 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)</h3>
<ul>
<li>AstraZeneca reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion. The company's stock gained around 10% over the past five days and <a href="https://www.benzinga.com/quote/AZN">has a 52-week high</a> of $75.81.</li>
<li>RSI Value: 82.50</li>
<li>AZN Price Action: Shares of AstraZeneca gained 5.4% to close at $75.03 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</h3>
<ul>
<li>On April 24, Boston Scientific reported better than expected first-quarter earnings and issued guidance. The company's stock gained around 8% over the past five days and has a <a href="https://www.benzinga.com/quote/BSX">52-week high</a> of $74.39.</li>
<li>RSI Value: 76.34</li>
<li>BSX Price Action: Shares of American Express gained 0.5% to close at $73.26 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)</h3>
<ul>
<li>On April 18, Elevance Health reported first-quarter revenues of $42.3 billion, up 0.9% year over year, marginally missing the consensus of $42.6 billion. "First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry," CEO Gail Boudreaux said. "We are making significant progress expanding Carelon's capabilities, scaling our flywheel for enterprise growth, and delivering results for all stakeholders." The company's stock jumped around 4% over the past month and has a 52-week high is $542.07.</li>
<li>RSI Value: 70.18</li>
<li>ELV Price Action: Shares of Elevance Health gained 1.1% to close at $539.68 on Thursday.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38452338/microsoft-alphabet-and-3-stocks-to-watch-heading-into-friday">Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday</a>

Short Ideas

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

FUSN

Top 4 Health Care Stocks That May Plunge This Month

Baird analyst Timothy Wojs maintains Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) with a Outperform and raises the price target from $435 to $465.

Baird Maintains Outperform on Carlisle Companies, Raises Price Target to $465

RBC Capital analyst Walter Spracklin maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Sector Perform and raises the price target from $211 to $215.

RBC Capital Maintains Sector Perform on Waste Management, Raises Price Target to $215

A former senator from North Dakota, Heidi Heitkamp, expressed skepticism on the Joe Biden-led administration&#8217;s proposed 44% capital gains tax, stating it has no chance of passing.
What Happened: President Biden&#8217;s proposal to increase the capital gains rate to 44.6% in the Fiscal Year 2025 Budget has sparked significant discussion.
The main proposal is to raise the long-term capital gains and qualified dividends rates to 37% for taxpayers with taxable income above $1 million, Forbes <a href="https://www.forbes.com/newsletters/andrewleahey/2024/04/24/biden-capital-gains-rate-proposal-446/?sh=150d2081ff64">reported</a>. The 44.6% figure would only apply if an additional proposal to increase the net investment income tax rate by 1.2 percentage points for income above $400,000 is also approved.
Therefore, the 44.6% rate is not a blanket increase but would only affect individuals with taxable income above $1 million and investment income above $400,000. This is a strategic policy maneuver, focusing on high earners rather than small-business owners.
The policy aims to level the playing field between high ordinary income and investment income earners.
However, on Thursday, Heitkamp expressed her doubts about the proposal during CNBC&#8217;s &#8220;Last Call,&#8221; calling it &#8220;a political document.&#8221;
"He wants to make the point that he's advocating for higher taxes on billionaires. He did this in this document. But there's no chance this is going to pass,&#8221; she said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"There's no chance this is going to pass," says <a href="https://twitter.com/HeidiHeitkamp?ref_src=twsrc%5Etfw">@HeidiHeitkamp</a> on the Biden Administration proposing a 44% capital gains tax. "President Biden wants to make the point that he's calling for higher taxes on billionaires." <a href="https://t.co/Hp3tG1bvBw">pic.twitter.com/Hp3tG1bvBw</a>
&mdash; Last Call (@LastCallCNBC) <a href="https://twitter.com/LastCallCNBC/status/1783641319232929796?ref_src=twsrc%5Etfw">April 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/earnings/24/04/38424840/us-stocks-brace-for-negative-start-amid-tech-earnings-disappointments-caution-ahead-of-data-worst-o?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta, IBM Drag Nasdaq Futures Lower: What&#8217;s Driving Premarket Action</a>
Why It Matters: The Biden administration has been pushing for higher taxes on the ultra-rich, a move that has been met with mixed reactions. Last year, Democratic representatives reintroduced a <a href="https://www.benzinga.com/government/23/12/36078017/billionaires-tax-bill-returns-to-congress-as-supreme-court-debates-whether-it-may-be-unconstitutiona">Biden-backed bill</a> that seeks to issue a levy of 25% on the wealthiest Americans, including unrealized gains on stocks, bonds, and real estate. The legislation, if passed, could reduce the fiscal deficit by $3 trillion over ten years.
Notably, some billionaires, including Warren Buffett, <a href="https://www.benzinga.com/personal-finance/24/04/38319480/warren-buffett-wants-higher-taxes-for-the-ultra-rich-including-himself-says-my-friends-and-i-hav">chairman of Berkshire Hathaway Inc.</a> have publicly supported higher taxes on the super-rich. Buffett has previously criticized Congress&#8217;s leniency towards billionaires and called for a more equitable tax policy.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/04/38374783/wall-street-set-to-open-higher-as-tesla-to-kick-off-magnificent-7-earnings-why-this-analyst-thinks-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">S&amp;P 500, Nasdaq Futures Climb Higher: Will Tesla Earnings Spark Rally Or Retreat?</a>
Photo via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Analyst Color

Government

Macro Economic Events

Regulations

Economics

Former Democratic Senator Says Biden's New Capital Gains Tax Proposal Aimed At Billionaires Has 'No Chance' Of Passing

Baird analyst Michael Halloran maintains A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) with a Neutral and raises the price target from $86 to $92.

Baird Maintains Neutral on A.O. Smith, Raises Price Target to $92

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Joint (JYNT – Research Report), Xtant Medical Hold...

Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trulieve Cannabis (TCNNF – Research Report), Xtant M...

Analysts Are Bullish on These Healthcare Stocks: Trulieve Cannabis (TCNNF), Xtant Medical Holdings (XTNT)

Xtant Medical GAAP EPS of -$0.03 in-line, revenue of $17.14M misses by $9.41M

Xtant Medical GAAP EPS of -$0.03 in-line, revenue of $28.1M beats by $1.55M

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Xtant Medical Holdings (XTNT – Research Report). The c...

Xtant Medical Holdings (XTNT) Receives a Buy from Craig-Hallum

Xtant Medical Holdings Inc. (XTNT) Q4 2023 Earnings Call Transcript

Xtant Medical files for $150M mixed shelf offering

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xtant Medical Hldgs (NYSEMKT:<a href="https://investorplace.com/stock-quotes/xtnt-stock-quote/">XTNT</a>) just reported results for the fourth quarter of 2023.<ul><li>Xtant Medical Hldgs reported earnings per share of -3 cents. This was below the analyst estimate for EPS of -2 cents.</li><li>The company reported revenue of $28.11 million.</li><li>This was 5.87% better than the analyst estimate for revenue of $26.55 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/xtnt-stock-earnings-xtant-medical-hldgs-for-q4-of-2023/">XTNT Stock Earnings: Xtant Medical Hldgs Misses EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XTNT Stock Earnings: Xtant Medical Hldgs Misses EPS, Beats Revenue for Q4 2023

Xtant Medical Holdings Inc (XTNT) has disclosed a new risk, in the Capital Markets category. Xtant Medical Holdings Inc. faces significant business...

Xtant Medical's Earnings at Risk: The Unhedged Perils of Currency Fluctuations

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rocket Pharmaceuticals (RCKT – Research Report), Liquidia Technol...

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)

CELC

JYNT

LQDA

ONCT

RCKT

TCNNF

Press Releases

Xtant Medical Highlights Growing Product Portfolio at NASS 2023

Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

Xtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023

Earnings

Xtant Medical Announces Record Third Quarter Revenue of $25 Million

Xtant Medical to Participate in Upcoming Investor Conferences

Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference

Financing

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

Align Tech

Atrion

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

Dentsply Sirona

Xtant Medical Holdings

BTIG

Craig-Hallum